Free Stipulation - District Court of Delaware - Delaware

Case 1 :07-cv-00360-JJF Document 25 Filed 01 /28/2008 Page 1 of 3 5
5
IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE
PFIZER, INC., ) A
PFIZER IRELAND PHARMACEUTICALS,)
WARNER-LAMBERT COMPANY, )
WARNER—LAl\/IBERT COMPANY, LLC ) V
and )
WARN ER—LAMBERT EXPORT LTD., )
)
Plaintiffs, ) Civil Action No. 07-3 60-JJF
» )
v. )
)
TEVA PHARMACEUTICALS USA, INC., )
A » )
Defendant. ) `
JOINT STIPULATION »
Defendant Teva Pharmaceuticals USA, Inc. ("Teva") and plaintiffs Pfizer, Inc., Pfizer
Ireland Pharmaceuticals, Warner-Lambert Company, Warner-Lambert Company, LLC and
Warner~Lambert Export Ltd. (collectively referred to as “Pfizer"), hereby stipulate and agree as
follows: »
1. Teva concedes that the manufacture, use, sale or offer for sale in the United
1 States, or importation into the United States, of the tablets that are the subject of ANDA No. 78-
1
i 773 would infringe claims 1, 2, ll and 12 of the patent-in-suit, U.S. Patent No. 5,273,995 ("the
‘995 patent") if claims 1, 2, 11 and 12 are not held invalid. ‘
2. Teva will not assert that claims 1, 2, 11 or 12 of the ‘995 patent are invalid for
failure to comply with the provisions of 35 U.S.C. § 112, il 4 (which is the subject of Ptizer’s
Interrogatory No. 4).
3. Teva will not assert, in this litigation, that the ‘995 patent is unenforceable due to
inequitable conduct.

Case 1 :07-cv-00360-JJF Document 25 Filed 01 /28/2008 Page 2 of 3

l
4. Pfizer covenants not to assert infringement under any section of 35 U.S.C. § 271
of claims 3, 4, 5, 7, 8, 9.or 10 of the ‘995 patent, or any corresponding claims in any reissue of
the ‘995 patent, with respect to the tablets that are the subject of ANDA No. 78-773 (ANDA
TABLETS) and the atorvastatin calcium salt active pharmaceutical ingredient when used to
make the ANDA TABLETS; ,
5. Pfizer hereby withdraws Document Request Nos. 7, 9, 14, 19, 21, 22, 23, 24, 25,
26, 30, 31, 32, 44 and 50, and Interrogatory Nos. 1, 3, 4 and 7.
6. Pfizer hereby withdraws Document Request bios. 1, 2, 4, 5, 6, 8, 10, 11, 16 and 27
except to the extent that they relate to documents which relate, reflect or refer to (a) any
comparison between the properties of [R-(R*,R*)]-2-(4-fluorophenyl)—[3,5-dihydroxy—5—(1 —
methylethyl)-3 —phenyl-4-[(phenylamino)-carbonyl]-1.H—pyrrole—1 -heptanoic acid or any salt
thereof and the properties of a racemic mixture of [R—(R*,R*)]—2~(4-f1uorophenyl)-B,6-
dihydroxy—5-(1—methylethyl)-3 —phenyl-44[(phenylamino)-carbonyl]-1H-pyrrole—1-heptanoic acid
and [S-(R*,R*)]-2-(4—fluorophenyl)—[3,5—dihydroxy—5—(1—methylethyl)-3—phenyl—4-
[(phenylamino)-carbonyl]-1H-pyrrole—1—heptanoic acid or any salt thereof; or (b) any
comparison between the properties ofthe R—trans isomer of 5—(4~fluorophenyl)-2—(l —
methylethyl)—N,4-—diphenyl—1-[2—(tetrahydro—4-hydroxy-6-oxo—2H—pyran—2—yl)ethyl]-1H-pyrrole—
3-carboxamide and a racemic mixture of the R-trans isomer of 5-(4-fluorophenyl)—2-(1-
l methylethyl)—N,4—diphenyl-1—[2-(tetrahydro—4—hydroxy—6-oxo-2H—pyran-2—yl)ethyl]—1H-pyrrole-
P 3~carboxamide and the S-trans isomer of` 5—(4—fluorophenyl)—2-(1—methylethy1)-N,4—diphenyl-1-
[2-(tetrahydro-4-hydroxy-6-oxo—2H—pyran—2-yl)ethyl]—1H—pyrrole—3-carboxamide.
7. _ Pfizer hereby withdraws Document Request Nos. 3, l7, 34, 39 and 4l to the
extent that they relate to infringement of` and/or the unenforceability of the ‘995 patent.
588713_1.DOC
- 2 -

l
Case 1 :07-cv-00360-JJF Document 25 Filed 01 /28/2008 Page 3 of 3 1
l
1
Dated: January 28, 2008
/s/ Jegijey B. Bova /s/ Richard D. Kirk
Rudolf E. Hutz (#484) Richard D. Kirk (#922)
Jeffrey B. Bove (#998) Ashley B. Stitzer (#3891)
Mary W. Bourke (#2356) BAYARD, P.A.
CONNOLLY BOVE LODGE & I-IUTZ LLP 222 Delaware Avenue, Suite 900
The Nemours Building I Wilmington, DE 19899-5130
1007 North Orange Street (302) 655-5000 , ,
P.O. Box 2207
Wilmington, DE 19899-2207 Attorneys for Defendant
Tel: (302) 658-9141 TEVA PHARMACEUTICALS USA, INC
Fax: (302) 658-5614
OF COUNSEL:
Attorneys for Plaintiffs David M. Hashmall
_ Frederick H. Rein
Emily L. Rapalino .
Joseph B. Crystal
GOODWIN PROCTER LLP _
599 Lexington Avenue
New York, NY 10022
Tel: (212) 813-8800
Fax: (212) 355-3333
IT IS SO ORDERED this day of , 2008.
United States District Judge
588713_l.DOC
. - 3 -